{"id":"placebo-infusion","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo Infusion","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:00:21.410022+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:00:26.635885+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo Infusion","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:00:26.988740+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo infusion is an inert substance administered intravenously that lacks active pharmaceutical ingredients. Its therapeutic effects, when observed, arise from psychological mechanisms including expectation, conditioning, and the patient-provider interaction rather than direct molecular action. This is typically used in clinical research as a control comparator to distinguish true drug effects from placebo responses.","oneSentence":"Placebo infusion produces therapeutic effects through patient expectation and the placebo effect rather than active pharmacological mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:05.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:00:28.976039+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05462730","phase":"PHASE2","title":"Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Thomas Engstrom","startDate":"2022-11-14","conditions":"ST Elevation Myocardial Infarction, Inflammatory Response, Myocardial Reperfusion Injury","enrollment":530},{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT05499130","phase":"PHASE2","title":"A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2022-09-30","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":290},{"nctId":"NCT03969004","phase":"PHASE3","title":"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-06-04","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":415},{"nctId":"NCT06128629","phase":"PHASE3","title":"MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)","status":"RECRUITING","sponsor":"Intellia Therapeutics","startDate":"2023-12-13","conditions":"Transthyretin Amyloidosis (ATTR) With Cardiomyopathy","enrollment":1200},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT07210515","phase":"PHASE3","title":"Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)","status":"RECRUITING","sponsor":"Ambros Therapeutics, Inc.","startDate":"2026-03","conditions":"Complex Regional Pain Syndrome Type I","enrollment":270},{"nctId":"NCT06533865","phase":"PHASE3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-19","conditions":"FHA (Functional Hypothalamic Amenorrhea)","enrollment":114},{"nctId":"NCT04751175","phase":"PHASE4","title":"Management of Pain in Lumbar Arthrodesis","status":"COMPLETED","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","startDate":"2013-07-04","conditions":"Pain, Postoperative","enrollment":128},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT06132256","phase":"PHASE2","title":"MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2023-12-11","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145},{"nctId":"NCT07273071","phase":"PHASE4","title":"Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine","status":"NOT_YET_RECRUITING","sponsor":"Theis S. Itenov","startDate":"2026-07","conditions":"Sepsis, Acute Infection, Severe Infection","enrollment":360},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT03540368","phase":"NA","title":"Tranexamic Acid for The Treatment of Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2018-07-01","conditions":"Gastrointestinal Bleeding","enrollment":48},{"nctId":"NCT05039840","phase":"PHASE2","title":"Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2021-11-10","conditions":"Systemic Lupus Erythematosus","enrollment":109},{"nctId":"NCT04297683","phase":"PHASE2, PHASE3","title":"HEALEY ALS Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Merit E. Cudkowicz, MD","startDate":"2020-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":1500},{"nctId":"NCT06290128","phase":"PHASE3","title":"A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-07-12","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic","enrollment":140},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT05139316","phase":"PHASE3","title":"A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-11-08","conditions":"Glycogen Storage Disease Type IA","enrollment":49},{"nctId":"NCT05072314","phase":"PHASE3","title":"Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial","status":"RECRUITING","sponsor":"Monash University","startDate":"2022-07-27","conditions":"Breast Cancer, Breast Cancer Female, Breast Conserving Surgery","enrollment":4300},{"nctId":"NCT05321121","phase":"PHASE4","title":"Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2021-11-12","conditions":"Rib Fractures, Pain, Acute","enrollment":41},{"nctId":"NCT07493577","phase":"PHASE1, PHASE2","title":"Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)","status":"NOT_YET_RECRUITING","sponsor":"Dr David Hasan, M.D.","startDate":"2026-07-23","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":82},{"nctId":"NCT06830798","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-02-24","conditions":"Delayed Graft Function, DGF, Kidney Transplant","enrollment":450},{"nctId":"NCT07211958","phase":"PHASE3","title":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2025-11-25","conditions":"Acute Myeloid Leukemias","enrollment":468},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07314060","phase":"PHASE2","title":"A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2026-03-19","conditions":"Generalized Pustular Psoriasis","enrollment":36},{"nctId":"NCT06337838","phase":"PHASE3","title":"Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-06-09","conditions":"Chronic Kidney Diseases, Acute Kidney Injury, Bleeding","enrollment":100},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT06077760","phase":"PHASE3","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Non-small Cell Lung Cancer","enrollment":868},{"nctId":"NCT06466135","phase":"PHASE2","title":"Study of WAL0921 in Patients With Glomerular Kidney Diseases","status":"RECRUITING","sponsor":"Walden Biosciences","startDate":"2024-07-02","conditions":"Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease","enrollment":96},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT06799247","phase":"PHASE3","title":"Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis","status":"RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2025-05-06","conditions":"Myasthaenia Gravis","enrollment":100},{"nctId":"NCT04003636","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-24","conditions":"Biliary Tract Carcinoma","enrollment":1069},{"nctId":"NCT07225569","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-29","conditions":"Hidradenitis Suppurativa","enrollment":144},{"nctId":"NCT06269393","phase":"PHASE3","title":"A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Thyroid Associated Ophthalmopathy","enrollment":53},{"nctId":"NCT06396065","phase":"PHASE3","title":"Phase III Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Summit Therapeutics","startDate":"2023-05-04","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT07362446","phase":"PHASE2","title":"Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Nyrada Pty Ltd","startDate":"2026-04-16","conditions":"Myocardial Infarction, Reperfusion Injury, AMI","enrollment":300},{"nctId":"NCT07088068","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-08-06","conditions":"Type 1 Diabetes Mellitus","enrollment":723},{"nctId":"NCT07094516","phase":"PHASE2","title":"A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-08-07","conditions":"Alzheimer's Disease","enrollment":407},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT07487545","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2026-03-31","conditions":"Healthy","enrollment":52},{"nctId":"NCT07486934","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1","status":"NOT_YET_RECRUITING","sponsor":"Dyne Therapeutics","startDate":"2026-04","conditions":"Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy","enrollment":150},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07488832","phase":"NA","title":"Intravenous Lidocaine Infusion in Lumbar Fusion Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2026-03-20","conditions":"Lumbar Fusion Surgery","enrollment":110},{"nctId":"NCT05184764","phase":"PHASE1, PHASE2","title":"Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2022-04-26","conditions":"Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia","enrollment":56},{"nctId":"NCT07212595","phase":"PHASE2","title":"Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy","status":"NOT_YET_RECRUITING","sponsor":"Stuart Goldstein, MD","startDate":"2026-04-01","conditions":"Acute Kidney Injury, Mechanical Ventilation","enrollment":30},{"nctId":"NCT05996835","phase":"PHASE2","title":"Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-18","conditions":"Acute Kidney Injury Due to Sepsis","enrollment":320},{"nctId":"NCT07200089","phase":"PHASE1","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":40},{"nctId":"NCT07024823","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-09","conditions":"Chronic Kidney Disease","enrollment":124},{"nctId":"NCT07224711","phase":"PHASE4","title":"The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-07-01","conditions":"Pain, Post Operative Analgesia, Opioid Consumption, Postoperative","enrollment":2290},{"nctId":"NCT07466108","phase":"NA","title":"Hemodynamic Effects of Intravenous Paracetamol in Patients Undergoing Emergency Laparotomy","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-03-18","conditions":"Paracetamol, Hypotension Drug-Induced, Emergency Surgery","enrollment":90},{"nctId":"NCT05405387","phase":"PHASE2","title":"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-05-03","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":120},{"nctId":"NCT05285891","phase":"PHASE4","title":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-12","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT04763343","phase":"PHASE3","title":"Ketamine Treatment of Youth Suicide Attempters","status":"RECRUITING","sponsor":"Tatiana Falcone, MD","startDate":"2022-06-27","conditions":"Suicide, Attempted","enrollment":60},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT06229483","phase":"PHASE3","title":"The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies","status":"RECRUITING","sponsor":"Stephen Lownie","startDate":"2024-04-03","conditions":"Brain Tumor, Bleeding","enrollment":102},{"nctId":"NCT05648968","phase":"PHASE3","title":"A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-30","conditions":"Warm Autoimmune Hemolytic Anemia (wAIHA)","enrollment":90},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT06589986","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-17","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":400},{"nctId":"NCT07048314","phase":"PHASE1, PHASE2","title":"Stem Cells for Erectile Dysfunction Post RALP","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03-10","conditions":"Erectile Dysfunction, Prostate Cancer","enrollment":40},{"nctId":"NCT06291376","phase":"PHASE3","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-03-29","conditions":"Immunoglobulin A Nephropathy, IgAN","enrollment":510},{"nctId":"NCT07462819","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Intravenous Stemis™ in Elderly Subjects With Mild to Moderate Frailty Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ji Yan Biomedical Co., Ltd.","startDate":"2026-04","conditions":"Frailty Syndrome","enrollment":12},{"nctId":"NCT07218380","phase":"PHASE3","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-12","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis","enrollment":450},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT07392372","phase":"PHASE1","title":"A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-09","conditions":"HIV -1 Infection","enrollment":61},{"nctId":"NCT07483346","phase":"PHASE1","title":"IASO-782 in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Shanghai IASO Biotechnology Co., Ltd","startDate":"2026-04-30","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT03875235","phase":"PHASE3","title":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-16","conditions":"Biliary Tract Neoplasms","enrollment":810},{"nctId":"NCT04899908","phase":"PHASE2","title":"Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-09-15","conditions":"Brain Cancer, Brain Metastases, Melanoma","enrollment":134},{"nctId":"NCT07482540","phase":"NA","title":"Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-06-01","conditions":"New Onset, Atrial Fibrillation","enrollment":140},{"nctId":"NCT06611111","phase":"EARLY_PHASE1","title":"Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2025-02-03","conditions":"Post-Treatment Lyme Disease","enrollment":44},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT04661540","phase":"PHASE2","title":"A Study of Auxora in Patients With Critical COVID-19 Pneumonia","status":"TERMINATED","sponsor":"CalciMedica, Inc.","startDate":"2021-03-02","conditions":"Pneumonia","enrollment":10},{"nctId":"NCT06426823","phase":"NA","title":"The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2023-11-01","conditions":"Blood Flow","enrollment":10},{"nctId":"NCT04639050","phase":"PHASE1, PHASE2","title":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-15","conditions":"Alzheimers Disease","enrollment":241},{"nctId":"NCT06935357","phase":"PHASE3","title":"A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Biogen","startDate":"2025-05-08","conditions":"Immunoglobulin A Nephropathy (IgAN)","enrollment":454},{"nctId":"NCT05746559","phase":"PHASE3","title":"ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-04-06","conditions":"Chronic Kidney Disease, CKD, Cardiac Disease","enrollment":736},{"nctId":"NCT07184801","phase":"PHASE3","title":"Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-10-01","conditions":"Medical Thoracoscopy","enrollment":56},{"nctId":"NCT05907096","phase":"PHASE2","title":"ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-02-17","conditions":"Delayed Graft Function","enrollment":103},{"nctId":"NCT07219043","phase":"PHASE2","title":"A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation","status":"RECRUITING","sponsor":"Biogen","startDate":"2026-01-05","conditions":"Microvascular Inflammation","enrollment":81},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT06599307","phase":"PHASE2","title":"The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-08-01","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":46},{"nctId":"NCT07287982","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy","status":"RECRUITING","sponsor":"argenx","startDate":"2025-12-19","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":60},{"nctId":"NCT07478003","phase":"PHASE3","title":"Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Thomas Engstrom","startDate":"2026-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":5204},{"nctId":"NCT06699849","phase":"PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-10","conditions":"Sickle Cell Disease Vaso-occlusive Crisis","enrollment":70},{"nctId":"NCT02504372","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":1177},{"nctId":"NCT03100149","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-06-27","conditions":"Parkinson's Disease","enrollment":316},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT07463521","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis","status":"NOT_YET_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2026-05-29","conditions":"Ocular Myasthenia Gravis","enrollment":120},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04029090","phase":"PHASE1","title":"A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-09-18","conditions":"Healthy Adult Subjects","enrollment":27},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DEPRESSION"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"FEELING OF DESPAIR"},{"count":1,"reaction":"HALLUCINATION"},{"count":1,"reaction":"HALO VISION"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"HYPERTENSIVE EMERGENCY"},{"count":1,"reaction":"INCREASED APPETITE"},{"count":1,"reaction":"IRRITABILITY"},{"count":1,"reaction":"MOOD SWINGS"}],"_approvalHistory":[],"publicationCount":666,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ADSC Infusion Therapy Placebo","Sodium chloride (NaCl)","lactated ringers","Placebo","Control"],"phase":"marketed","status":"active","brandName":"Placebo Infusion","genericName":"Placebo Infusion","companyName":"American CryoStem Corporation","companyId":"american-cryostem-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":7,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:00:28.976039+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}